CureMetrix and Therapixel have announced a partnership to integrate their complementary mammography AI technologies, creating what the companies describe as a “2-for-1” screening approach that addresses both breast cancer detection and cardiovascular risk assessment through a single mammogram examination.
The agreement brings together CureMetrix’s cmAngio®—the first and only FDA-cleared AI software that detects and localizes breast arterial calcifications (BAC)—with Therapixel’s MammoScreen®, a comprehensive breast cancer screening AI that analyzes 2D, 3D, and prior mammograms. According to the companies, cmAngio is currently deployed at hundreds of sites across the United States and has been offered to almost 1 million women.
Expanding Clinical Value Beyond Cancer Detection
Breast arterial calcifications represent calcium deposits along breast artery walls that appear as incidental findings in 12% to 42.5% of screening mammograms, according to research published in the Journal of Breast Imaging. However, less than 5% of BAC instances are currently reported by radiologists, despite emerging evidence linking these calcifications to cardiovascular disease risk in women.
Research published in Circulation: Cardiovascular Imaging found that postmenopausal women with breast arterial calcifications detected on mammography are 51% more likely to experience stroke or develop heart disease compared to women without these calcifications. More recently, a study published in JACC: Advances demonstrated that women with BAC have three times higher odds of developing adverse outcomes, including myocardial infarction, stroke, heart failure, and mortality.
“By integrating cmAngio with Therapixel’s MammoScreen, we are broadening our reach, unifying installation for customers, and helping radiologists deliver deeper, data-driven insights that can improve outcomes for patients.” — Kevin Harris, President, CureMetrix
“This partnership aligns two innovators committed to transforming women’s health,” said Kevin Harris, President of CureMetrix. “cmAngio is live at hundreds of sites across the US and has been offered to almost 1 million women. By integrating cmAngio with Therapixel’s MammoScreen, we are broadening our reach, unifying installation for customers, and helping radiologists deliver deeper, data-driven insights that can improve outcomes for patients.”
The integrated approach addresses a persistent gap in mammography workflows: while breast arterial calcifications are commonly visible on screening mammograms, the absence of standardized guidelines for identifying, evaluating, and reporting BAC has led to inconsistent practices across institutions. cmAngio’s AI-based detection provides automated identification and localization of these findings, enabling radiologists to systematically identify women who may benefit from cardiovascular risk evaluation.
Comprehensive Breast Cancer Screening with Workflow Integration
MammoScreen brings a different set of capabilities focused on breast cancer detection and radiologist efficiency. The AI solution incorporates multiple data sources—current 2D and 3D images plus prior screenings—to generate a scoring system that assists radiologists in reading mammograms. According to the company, clinical studies have demonstrated that MammoScreen can detect 42% of cancers one year before diagnosis and 38.5% two years before diagnosis.
“Two best-in-class products, MammoScreen and cmAngio, now combine to empower radiologists to work smarter, improve quality and consistency, and make more informed decisions in breast imaging.” — Matthieu Leclerc-Chalvet, CEO, Therapixel
“We’re proud to partner with CureMetrix to bring even more clinical value to our customers,” said Matthieu Leclerc-Chalvet, CEO of Therapixel. “Two best-in-class products, MammoScreen and cmAngio, now combine to empower radiologists to work smarter, improve quality and consistency, and make more informed decisions in breast imaging. Improving women’s health and patient outcomes is our mission, and by detecting breast arterial calcifications that often go unnoticed or unreported, we are advancing that mission.”
Beyond cancer detection, MammoScreen provides image quality analysis, patient health history alerts, and draft report generation, according to Therapixel. The company states that clinical studies have shown the technology reduces reader fatigue and inter-reader variability, potentially improving consistency and equity in patient care. By increasing specificity, MammoScreen aims to lower unnecessary recalls—reducing anxiety and inconvenience for patients while improving operational efficiency.
Strategic Implications for Women’s Health Screening
The partnership reflects broader recognition within radiology that mammography examinations—already performed annually by millions of women—represent an underutilized opportunity for cardiovascular risk screening. Cardiovascular disease remains the leading cause of death among women in the United States, yet women face barriers including lack of reliable, sex-specific screening modalities and atypical symptom presentation that can delay diagnosis.
The integration strategy addresses practical implementation challenges that have historically limited AI adoption in mammography. Rather than requiring separate installations, vendor relationships, and workflow integrations for each AI application, the unified platform approach consolidates technical infrastructure while expanding clinical capabilities. This operational efficiency may prove particularly relevant for community hospitals and imaging centers where IT resources and capital for multiple AI deployments are limited.
The partnership also positions both companies to leverage each other’s market presence and customer relationships. CureMetrix brings established distribution with hundreds of sites already using cmAngio, while Therapixel recently announced deployment of MammoScreen across Onsite Women’s Health’s 150+ locations nationally. The combined reach potentially accelerates adoption of both technologies compared to independent market development efforts.
Clinical Workflow and Reporting Considerations
The practical implementation of integrated breast cancer and cardiovascular risk screening raises workflow and follow-up questions that will likely evolve as adoption expands. While cmAngio provides detection and localization of breast arterial calcifications, the device is not a diagnostic tool for cardiac disease and does not predict disease development—it identifies an imaging biomarker that warrants clinical consideration.
Current medical practice lacks standardized protocols for how radiologists should communicate BAC findings to referring physicians, what cardiovascular evaluation should follow positive findings, and how primary care providers should incorporate this information into overall risk assessment. Some healthcare systems have begun developing pathways that route patients with detected BAC to cardiovascular risk evaluation, but these workflows remain institution-specific rather than standardized across radiology practice.
The partnership’s success in improving patient outcomes will depend partly on whether radiologists, cardiologists, and primary care providers develop coordinated approaches to acting on BAC findings. Simply detecting more incidental findings without clear care pathways could create uncertainty for patients and providers alike—a dynamic that has characterized other AI implementations in radiology where increased sensitivity produces actionable findings that existing workflows aren’t designed to handle efficiently.
For breast cancer screening specifically, MammoScreen’s integration of prior images and pre-reporting features aims to address radiologist workflow efficiency—a persistent challenge as imaging volumes grow while the radiologist workforce remains constrained. Whether the combined platform delivers measurable improvements in detection rates, reading time, and diagnostic confidence beyond each technology operating independently will require ongoing clinical validation and real-world performance monitoring.
Market Context and Competitive Landscape
The partnership enters a competitive landscape where multiple vendors offer AI solutions for mammography, though most focus exclusively on cancer detection rather than the dual cancer-cardiovascular approach. The integration strategy differentiates CureMetrix and Therapixel from point solutions while potentially creating integration complexity that could affect implementation timelines and technical support requirements.
Both companies bring established regulatory clearances—cmAngio holds FDA clearance for both Hologic and GE Healthcare mammography platforms, while MammoScreen has FDA clearance for 2D and 3D mammography and CE marking for European markets. This regulatory foundation enables immediate commercial deployment in key markets, though reimbursement pathways for AI-assisted BAC detection and its subsequent cardiovascular evaluation remain evolving.
The companies did not disclose financial terms, technical architecture for integration, or timeline for unified product availability. Customer pricing, whether sites will license both technologies together or separately, and how the integration affects existing customer contracts also remain unspecified.
For women undergoing mammography screening, the partnership’s vision of comprehensive risk assessment through routine imaging represents meaningful progress—provided that health systems develop the care coordination infrastructure to act effectively on the insights these technologies provide. The real measure of success will be whether detecting both cancer and cardiovascular risk markers earlier translates to improved health outcomes through timely intervention.
— This original article was created with AI support.
